Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2025; 17(3): 103854
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.103854
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.103854
Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression
Jian-Zhong Shu, Department of Encephalopathy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400015, China
Jian-Zhong Shu, Yu-Han Huang, Xiao-Hong He, Feng-Ying Liu, Qian-Qian Liang, Xue-Tong Yong, Yong-Fang Xie, School of Life Health Information Science and Engineering, Chongqing University of Posts and Telecommunications, Chongqing 400065, China
Jian-Zhong Shu, College of Integrated Traditional Chinese and Western Medicine, Chongqing University of Traditional Chinese Medicine, Chongqing 402760, China
Yong-Fang Xie, Institute of Bioinformatics, Chongqing University of Posts and Teleco
Co-first authors: Jian-Zhong Shu and Yu-Han Huang.
Author contributions: Shu JZ and Huang YH contribute equally to this study as co-first authors; Shu JZ, Huang YH, He XH, Liu FY, Liang QQ, Yong XT and Xie YF designed the research study; Shu JZ, Huang YH, Liu FY, Liang QQ and Yong XT performed the literature collection and screening and drafted the original manuscript; Huang YH, He XH, Liu FY, Liang QQ and Yong XT reviewed and edited the manuscript and contributed to the visualization; He XH and Xie YF were responsible for the project administration and funding acquisition; He XH, Huang YH and Xie YF provided conceptualization.
Supported by Natural Science Foundation of Chongqing, No. cstc2021jcyj-msxmx0848; Chongqing Bishan Scientific Research Project, No. BSKJ2022006; National Natural Science Foundation of China, No. 81773954; National College Students Innovation and Entrepreneurship Program, No. 202310617015.
Conflict-of-interest statement: All the authors solemnly declare that there are no conflicts of interest in aspects such as finance, personal relationships, and intellectual property rights that might affect the fairness, objectivity, and interpretation of the research results.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Fang Xie, PhD, Professor, School of Life Health Information Science and Engineering, Chongqing University of Posts and Telecommunications, No. 2 Chongwen Road, Nanshan Street, Nan'an District, Chongqing 400065, China.
Received: December 12, 2024
Revised: January 17, 2025
Accepted: February 12, 2025
Published online: March 27, 2025
Processing time: 113 Days and 1.6 Hours
Revised: January 17, 2025
Accepted: February 12, 2025
Published online: March 27, 2025
Processing time: 113 Days and 1.6 Hours
Core Tip
Core Tip: This review elaborates in detail on the comparison of the gut microbiota between metabolic dysfunction-associated steatotic liver disease patients and healthy individuals, between metabolic dysfunction-associated fatty liver and metabolic dysfunction-associated steatohepatitis, as well as between the stages of mild fibrosis and significant fibrosis. It reveals the changes in the production and action mechanisms of short-chain fatty acids, bile acids, and lipopolysaccharides brought about by the changes in the gut microbiota. In addition, it also explores the regulation of the gut microbiota in the disease by using probiotics and the production and inhibition of related disease factors.